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Summary
Carbohydrate-deficient–glycoprotein syndrome type 1
(CDG1; also known as “Jaeken syndrome”) is an au-
tosomal recessive disorder characterized by defective gly-
cosylation. Most patients show a deficiency of phos-
phomannomutase (PMM), the enzyme that converts
mannose 6-phosphate to mannose 1-phosphate in the
synthesis of GDP-mannose. The disease is linked to chro-
mosome 16p13, and mutations have recently been iden-
tified in the PMM2 gene in CDG1 patients with a PMM
deficiency (CDG1A). The availability of the genomic se-
quences of PMM2 allowed us to screen for mutations
in 56 CDG1 patients from different geographic origins.
By SSCP analysis and by sequencing, we identified 23
different missense mutations and 1 single-base-pair de-
letion. In total, mutations were found on 99% of the
disease chromosomes in CDG1A patients. The R141H
substitution is present on 43 of the 112 disease alleles.
However, this mutation was never observed in the ho-
mozygous state, suggesting that homozygosity for these
alterations is incompatible with life. On the other hand,
patients were found homozygous for the D65Y and
F119L mutations, which must therefore be mild muta-
tions. One particular genotype, R141H/D188G, which
is prevalent in Belgium and the Netherlands, is associ-
ated with a severe phenotype and a high mortality. Apart
from this, there is only a limited relation between the
genotype and the clinical phenotype.
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Introduction
Carbohydrate-deficient glycoprotein (CDG) syndromes
are a series of genetic disorders characterized by defec-
tive N-glycosylation of serum and cellular proteins (Jae-
ken et al. 1980, 1997b; Jaeken and Carchon 1993; Jae-
ken and Casaer 1997). At present, four types of CDG
have been described on the basis of serum transferrin
isoelectrofocusing (IEF). CDG type 1 (CDG1 [MIM
212065]) is the most frequent type. It is a severe disorder
that presents neonatally. There is a life-threatening liver
insufficiency (with an overall 20% mortality during the
neonatal period), combined with a severe cerebellar dys-
function and peripheral neuropathy, leading to severe
psychomotor retardation. These children also have skel-
etal deformities and a characteristic deposition of adi-
pose tissue (Jaeken and Carchon 1993; Jaeken et al.
1997b). CDG type 2 (CDG2), type 3 (CDG3), and type
4 (CDG4) represent only two cases each (Stibler et al.
1993, 1995; Jaeken et al. 1994). CDG2 is caused by a
deficiency of UDP-GlcNAc:a-6-D-mannoside b-1,2-N-
acetylglucosaminyltransferase 2 (GnT 2), located in the
Golgi apparatus, and mutations in the GnT 2 gene
(MGAT2) on 14q21 have been identified (Jaeken et al.
1994; Tan et al. 1996). The causes of CDG3 and CDG4
remain unknown.
CDG1 is inherited in an autosomal recessive manner,
and its locus has been mapped to chromosome 16p13
(Martinsson et al. 1994). Linkage to the region between
D16S406 and D16S500 has been confirmed in 10 of 11
informative families (Matthijs et al. 1996). In one family
with two affected siblings, the disease was, however, not
linked to chromosome 16p, indicating genetic hetero-
geneity for CDG1 (Matthijs et al. 1996).
Biochemical evidence has long suggested a basic defect
in the synthesis of the dolichol-P-oligosaccharides (syn-
thesis of the asparagine-N-linked oligosaccharides) in
the endoplasmic reticulum (ER) (Jaeken et al. 1984;
Wada et al. 1992). In 1995, Van Schaftingen and Jaeken
(1995) identified a deficiency of phosphomannomutase
(PMM) activity in patients with CDG1. This observation
has been confirmed in more than 50 CDG1 patients from
different geographic origins (Jaeken et al. 1997a). We
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have recently cloned the human PMM gene PMM2 and
have shown that it is the CDG1 gene (Matthijs et al.
1997a). Another PMM gene, PMM1, could be assigned
to chromosome 22q13 (Matthijs et al. 1997b). Both
PMM1 and PMM2 have been expressed in Escherichia
coli and have been found to be active proteins (Pirard
et al. 1997; E. Van Schaftingen and M. Pirard, unpub-
lished data). We have previously reported 11 missense
mutations in 16 CDG1 patients with a documented
PMMdeficiency (CDG1A) (Matthijs et al. 1997a). These
mutations have been identified at the cDNA level, after
reverse transcriptase–PCR amplification, followed by
SSCP analysis and sequencing. To search for mutations
in genomic DNA, the PMM2 intron/exon structure has
been determined, whereby eight exons have been iden-
tified (Schollen et al. 1998), and primers flanking each
translated exon have been designed. We here describe
the results of an exhaustive mutation analysis of the




Fifty-six patients from 12 countries were included in
the study; all except 2 were of Caucasian origin. A di-
agnosis of CDG1 was made in all these patients, on the
basis of clinical manifestations, and was substantiated
by the typical IEF pattern of serum transferrins: there is
both a strong reduction in the intensity of the normal
tetrasialotransferrin band and a concomitant increase in
the disialo- and asialotransferrin concentration. PMM
deficiency was documented in most cases (see table 1
and the Results section). The clinical features of CDG1
patients have recently been reviewed by Jaeken and Ca-
saer (1997) and Jaeken et al. (1997b). In brief, the neu-
rological picture includes abnormal eye movements,
combined with slow head movements in the neonatal
period, and axial hypotonia with hyporeflexia. Most
children present with an alternating strabismus. There
is a severe psychomotor retardation and failure to thrive,
with ataxia and, sometimes, deafness. Additional fea-
tures, presenting after infancy, are hypogonadism, reti-
nitis pigmentosa, joint contractures, and strokelike ep-
isodes. Most patients never attain the ability to walk
without support, but there is no regression. Other symp-
toms include mild facial dysmorphism (with large, some-
what dysplastic ears), skeletal deformities, and a typical
subcutaneous deposition of adipose tissue (“fat pads”).
There is a mild to moderate hepatomegaly, and some
infants develop pericardial effusion and/or cardiomy-
opathy. Approximately 20% of the patients die before
the age of 5 years, as a consequence of liver failure,
severe infection, cardiac insufficiency, nephrotic syn-
drome, or status epilepticus. Salient features in some
patients are listed in table 1.
The blood samples and/or fibroblast or lymphoblast
cultures from patients were provided to us after a request
for enzymatic assays and molecular diagnosis, and the
referring physicians and the families have been informed
about the results. Amniocytes were analyzed in the con-
text of prenatal diagnosis.
SSCP Analysis and Sequencing
DNA was isolated either from fresh blood or from
fibroblast or lymphoblast cultures from patients by use
of a high-salt-extraction procedure. On the basis of the
available sequence, primers were designed for the PCR
amplification of nine DNA fragments suitable for SSCP
analysis. One primer in each pair was labeled with FITC.
The primer sequences are given in table 2. PCR reactions
were typically done in 25 ml, and the cycling conditions
were 30 s at 95C, 30 s at 50–60C, and 30 s at 72C,
for 32 cycles. A 10–15-ml portion of each PCR product
was mixed with an equal volume of formamide and then
was denatured for 5 min at 95C, loaded onto a non-
denaturing polyacrylamide gel (0.5 # Hydrolink MDE
[J. T. Baker] in 0.6 # TBE [10 # TBE  1 M Tris,
0.82 M boric acid, and 10 mM EDTA]), and electro-
phoresed for 10 h at 4C at 400 V. The gels were directly
scanned on a Fluorimager (Vistra), and the signals were
analyzed with the ImagequaNT software (Molecular
Dynamics).
The PCR fragments were sequenced by cycle sequenc-
ing or solid-phase sequencing. Prior to cycle sequencing
with the Thermosequenase kit (Amersham), the PCR
fragments were purified by use of the Qiaquick-PCR
purification kit (Qiagen), and, typically, 50–100 ng was
used with 1 pmol of fluorescently labeled primer, for
15–22 cycles. Solid-phase sequencing using a biotiny-
lated template and streptavidin-coated DynaBeads (Dy-
nal) was done according to established procedures.
Results
Fifty-six patients and their affected siblings were in-
cluded in this series. Included are three pairs of patients
in which each pair has at least one common ancestor
(table 1). The diagnosis of CDG1 with PMM deficiency
was confirmed biochemically in 46 patients for whom
fibroblasts, lymphoblasts, or fresh leukocytes were avail-
able; in 2 of these patients, a partial deficiency of PMM
was found in fibroblasts (patients 47 [SAO] and 48
[GSS]), and, in 1 family (family 4, patients FG and FP,
both affected), intermediate values were measured in
lymphoblasts. From the remaining 10 patients, whose
diagnosis had been made previously on clinical grounds,
no cells were available for the enzymatic assay; in 7 of
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Table 1
PMM2 Mutations in 57 CDG1 Patients of Different Geographic Origins
Patient(s) Family
PMM Activitya
(mU/mg protein) Mutation(s) 1 Mutation(s) 2 Origin Special Feature(s)
1. RJM 33 NAb V44A R141H Ecuador
2. AB 37 1.02(f), .1(am)c D65Y R141H France Died at age 4 mo (he-
patic insufficiency)
3. SFd 16 .13(le) Y106C R141H Belgium
4. LMd 30 .09(le), .50(f) A108V R141H France
5. PSd 17 .10(f) P113L R141H Belgium Mild dysmorphy (Jae-
ken et al. 1980; Jae-
ken and Casaer
1997)
6. KS 21 NAb P113L R141H Netherlands
7. SFX .32(f) P113L R141H Germany
8. WCd 38 .0(f) P113L R141H Germany
9. MCd .19(f) P113L R141H France Severe gastrointestinal
symptoms
10. FRL .26(f) P113L R141H Portugal
11. HSJ 39 .11(f) F119L R141H Netherlands
12. SWM 26 .04(le) F119L R141H Netherlands
13. NP 6 NAb F119L R141H Netherlands
14. PLd .19(f) F119L R141H Netherlandse Died at age 6 years
15. SEd 5 NAb F119L R141H Netherlandsf
16. HRd 31 .17(f) F119L R141H Germany
17. OM 24 .16(f) F119L R141H Germany
18. PS 28 .26(f) F119L R141H Germany
19. DD .03(f) F119L R141H Germany
20. HE 45 NA, g.35(am)c F119L R141H France
21. MR 7 NAg F119L R141H France
22. RDd 35 .13(f) F119L R141H UK
23. KB .17(f) F119L R141H US
24. MMid 27 .0(f) F119L R141H US
25. FG, FPd 4 2.75(Ly), 2.2(Ly)h V129M R141H Italy (Sicily)
26. LN .44(f) V129M R141H US Died
27. BAd 9 .05(f) P131A R141H France
28. MMa .41(f) I132T R141H Italy
29. RPd .43(f) R162W R141H UK
30. BJ 14 .02(f) D188G R141H Belgium Died
31. BI 2 !.1(f) D188G R141H Belgiumi Died
32. LA 2 .17(f) D188G R141H Belgiumi
33. AV 47 NAg D188G R141H Netherlands Died
34. JI 1 .21(f) D188G R141H Netherlands Died (nephrotic syn-
drome) (Van der
Knaap et al. 1996)
35. WH 48 .16(f) G208A R141H US
36. CF, CAd 3 .33(Ly), .25 (Ly)h N216I, 699g/a R141H Italy (Sicily)
37. HStd 15 .10(f) V231M R141H Belgium Died
38. HN 29 .15(le) V231M R141H Belgium Severe gastrointestinal
syndrome
39. LA, LF .27(f), .98(f)h V231M R141H Peru
40. IS .64(f) V231M R141H Italy
41. CM 22 .47(f) V231M R141H US
42. HJ .90(f) V231M R141H US
43. MCCd 12 .0(f) T237M R141H Spain
44. TLP .64(f) D65Y D65Y Portugal
45. RMan 10 NAb N101K 324 del g Germany
46. PG NAb F119L F119L Netherlandse
47. SAO 1.80(f) R123G, 324g/a V44A Spain
48. GSS .09(f) R123G, 324g/a P113L Spain Pubertal development
(Pineda et al. 1996)
(Continued)




(mU/mg protein) Mutation(s) 1 Mutation(s) 2 Origin Special Feature(s)
49. SN 5 .15(f) R123G, 324g/a F119L Netherlandsf
50. RW 32 NAb R123G, 324g/a R162W Netherlands
51. DBE 8 .04(le) R123G, no
polymorphim
F119L France
52. HA 20 .29(f) R123G, no
polymorphism
Y229S Japan
53. VC .11(le) G175R P113L Belgium
54. SN, SJ .43(f), .19(f)h T237R, A233T P113L Germany
55. LS 43 .04(f) T237R T237M, A233T France
MM, MY .83(f), .42(f)h R238P ?? Japan
a f  fibroblasts of index patient; le  leukocytes of index patient; ly  lymphoblasts of index patient; and am  amniocytes. Mean  SD
control activities were 2.46  .48 in leukocytes ( ); 3.77  .86 in fibroblasts ( ), and 6.7  1.0 in amniocytes ( ).n  12 n  3 n  3
b No cells were available; mutation analysis was done on DNA from the patient.
c Obtained from amniocytes of a sibling with the same genotype.
d Patient has been reported elsewhere (Matthijs et al. 1997a).
e Two patients sharing disease alleles through a common ancestor.
f Two patients sharing disease alleles through a common ancestor.
g No patient material was available; genotype was derived from mutation analysis of parents.
h In two siblings with the same genotype.
i Two patients sharing disease alleles through a common ancestor.
Table 2
Sequence of Oligonucleotide Primers Used in PCR and SSCP Analysis of the Eight Exons of PMM2
Exon Name Sequence Name Sequence
Annealing Temperature
(C)
1 UP3B AGCGGCCGAACCCGGAAGTTC int0R fitc AGCAGCCGCCGGCCGCCAC 60
2 int1UB GGTCTCCTGATTATTGTGTGGC int2Rbis fitc GGCAGCCTATGATACTTG 55
3 int2FB GATTCTTTGCATTCTAAGTG int3R fitc TCCTAGAGGCATTCATTGTG 50
4 int3F CTGGGTTTGCTATGAAGCTG int4R fitc ACCATGTGACACTACGCTATG 60
5Aa intU2 GCACAGAGCTGAGAAACATT 2B fitc TGCGTTCTTCTTGGCTGCAGC 60
5Ba 3A fitc GGTACTTTCATTGAATTCC int4R GTGTTGGGATTACAGGCATG 55
6 int5F fitc CCAGTAGTTAAAACTGTGCT int6RB CCAAGTTTGGAACACAGGCA 55
7 int6F TCAGTGACATATCATTAGCC int6R fitc CCATCAAGCGCAAATGC 55
8 int7FB TCCAGGGTCACATCAGCAATGG 4B1 fitc GGAGAACAGCAGTTCACAG 52
a Exon 5 is analyzed in two fragments.
these cases (patients RJM, KS, NP, SE, PG, RW, and
RMan), DNA from the patient was available for anal-
ysis, whereas, in the remaining 3 cases (patientsHE,MR,
and AV), the mutation screening needed to be done on
DNA from the parents; in 2 of these 3 cases (patients
HE and AV), the clinical diagnosis was substantiated by
the measurement of intermediate PMMactivities in fresh
leukocytes from the parents.
The mutation screening was done by a nonradioactive
SSCP analysis of fragments amplified from genomic
DNA. The PCR fragments encompassed the individual
exons and the flanking sequences. Whenever a fragment
revealed an aberrant SSCP pattern, the corresponding
exon was sequenced.
With this approach, 20 different mutations were iden-
tified by SSCP in 56 patients (by deduction from the
parents’ genotypes, when applicable). For those patients
in whom no or only one mutation was identified by SSCP
analysis, the entire coding region was sequenced. Four
mutations were not revealed by SSCP analysis under the
described conditions but were identified after sequenc-
ing; these mutations are 131TrC (V44A), 303CrG
(N101K), 623GrC (G208A), and 713GrC (R238P), in
exons 2, 4, 7, and 8 respectively. Also, the mutations
484CrT (R162W) and 523GrC (G175R) in exon 6
were not easily identifiable, because of the presence of
two frequent polymorphisms in the flanking regions of
the exon. In total, mutations were found in 111 (99%)
of 112 disease chromosomes. In one Japanese patient,
heterozygous for one mutation at the genomic level, a
second mutation could not be found. Southern blot anal-
ysis has excluded major rearrangements of the gene in
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Figure 1 Schematic diagram of PMM2 cDNA, depicting the location of the various mutations found in the gene, with the exons indicated
below the diagram. Because, at present, nothing is known about possible domains in the protein, the degree of similarity with the yeast SEC53,
Candida albicans PMM, and human PMM1 has been represented: the black bands denote amino acid residues that are perfectly conserved
among the four proteins; the gray-shaded bands denote partial conservation; and the blank bands denote residues that are not conserved. Only
mutation R238P affects a residue that is not conserved. Mutations that have relatively frequently been encountered in this study are indicated
in boxes bordered by the thicker lines.
this patient (data not shown). The mutational spectrum
thus consists of 23 missense mutations and only one
single-base-pair deletion (fig. 1 and table 3). This dele-
tion of a G at position 324 in exon 4 causes a frameshift
and premature stop (fig. 2).
Forty-three patients were heterozygous for the R141H
mutation, but not a single patient was found to be ho-
mozygous for this mutation. Given the frequency of the
R141H mutation (the allele frequency, by counting, is
40% in the 54 Caucasians in this study), eight homo-
zygotes are expected in this sample, on the basis of the
Hardy-Weinberg equation ( ; ;2x  23.4 df  1 P !
). The most frequent genotype is the R141H/.00001
F119L combination (14 patients). One patient was ho-
mozygous for the relatively frequent F119L mutation
(fig. 3), which is in accordance with Hardy-Weinberg
equilibrium, and one was homozygous for the D65Y
mutation; the latter is a rare mutation, and the disease
allele was probably inherited from a common ancestor
of the parents.
In two patients, three different amino acid substitu-
tions were identified. In patient SN (and in the affected
sibling SJ), the A233T and T237R mutations are syn-
tenic, as deduced from the parental genotype. In patient
LS, the T237M and A233T mutations are probably on
the same chromosome—paternal DNAwas not available
for analysis, but the mother carried only the T237R
mutation.
Discussion
PMM Deficiency and Mutations in the PMM2 Gene
Both the localization of the PMM2 gene, encoding an
active PMM, on chromosome 16 and the identification
of mutations in this gene that segregate with the disease
(Matthijs et al. 1997a) gave conclusive support to the
biochemical evidence that PMM deficiency is the basis
for CDG1A (Van Schaftingen and Jaeken 1995; Jaeken
et al. 1997a). This conclusion is now strengthened by
the fact that, in almost all cases with a documented
PMM deficiency, we found mutations in the PMM2
gene. In one case, a second mutation was not found,
despite the fact that all exons were scrutinized by se-
quencing. The other mutation is probably in a regulatory
region of the gene.
Recent work has shown that PMM deficiency is found
in a majority of—but not in all—patients with CDG1.
In these patients, there is no reason to search for mu-
tations in the PMM2 gene. Accordingly, in the family in
which linkage to chromosome 16 could be excluded
(Matthijs et al. 1996), no PMM deficiency was found
in the propositus (authors’ unpublished results). Because
of this heterogeneity, PMM assays are still useful for
diagnosis. The only drawback of these measurements is
that, in some cases, the activity found in fibroblasts or
in lymphoblasts still represents as much as ∼30% of the
control value (e.g., see patients 2, 25, and 39), whereas
in other samples, derived either from the same patients
or from other patients with the same genotype, the ac-
tivity was !5% of the control activity. This problem has
not been encountered in assays performed with fresh
material such as leukocytes or liver. In the latter cases,
a profound deficiency has always been observed. We
have, at present, no explanation for these discordant
findings. One possibility is that PMM1 or the mutant
forms of PMM2 become overexpressed after several pas-
sages in culture.
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Table 3
Mutations in the PMM2 Gene
Exon Mutation Codon Change Amino Acid Change No. of Occurrencesa Conservation Statusb
2 131TrC GTArGCA V44A 2 Conserved
3 193GrT GATrTAT D65Y 3 Conserved
4 303CrG AACrAAG N101K 1 Not conserved
4 317ArG TACrTGC Y106C 1 Conserved
4 324 delG Frameshift ) 1 )
4 323CrT GCGrGTG A108V 1 Semiconserved
4 338CrT CCGrCTG P113L 9 Conserved
5 357CrA TTCrTTA F119L 18 Conserved
5 368GrA CGArCAA R123G 6 Conserved
5 385GrA GTGrATG V129M 2 Semiconserved
5 391CrG CCTrGCT P131A 1 Conserved
5 395TrC ATTrACT I132T 1 Conserved
5 422GrA CGCrCAC R141H 43 Conserved
6 484CrT CGGrTGG R162W 2 Conserved
6 523GrC GGArCGA G175R 1 Conserved
7 563ArG GACrGGC D188G 5 Conserved
7 623GrC GGArGCA G208A 1 Conserved
8 647ArT AATrATT N216I 1 Conserved
8 686ArC TACrTCC Y229S 1 Conserved
8 691GrA GTGrATG V231M 6 Conserved
8 697GrA GCGrACG A233Tc 2c Conserved
8 710CrT ACGrATG T237M 2 Conserved
8 710CrT ACGrAGG T237R 2 Conserved
8 713GrC CGCrCCC R238P 1 Semiconserved
a In the series of 112 disease alleles reported in this study.
b Compared with human PMM1, yeast PMM (SEC53), and Candida albicans PMM.
c A233T is observed in combination with the T237R mutation (patient 54) and with the T237M mutation
(patient 55).
PMM measurements are also useful for the identifi-
cation of carriers. If cells from an affected child are not
available, indirect evidence can be obtained from the
PMM activities in leukocytes from the parents. This has
proved worthwhile in two cases with an urgent request
for prenatal diagnosis, in which we derived information
on the PMM deficiency from the parents, before initi-
ating the molecular analysis. In view of the genetic het-
erogeneity, prenatal testing should be offered only in
families with a documented PMM deficiency and with
mutations in PMM2. Thus far, we have combined en-
zymatic measurements and mutation analysis for pre-
natal diagnosis (Matthijs et al. 1998).Molecular analysis
is the most dependable test for prenatal diagnosis.
Characteristics of the Mutations
Of the 24 different mutations that were identified, 20
were detectable by SSCP; among these 20 were the most
frequent ones, such as R141H, P113L, F119L, V231M,
and D188G. In practice, in only 1 of the 56 patients
with mutations (patient MM [and the sibling MY]), no
aberrant fragment was detected by SSCP analysis,
whereas in the other patients at least one mutation was
detected by SSCP alone. Given that the gene contains
only eight exons, the SSCP analysis represents a fairly
simple, reliable, and cost-effective approach for the mo-
lecular analysis of CDG1A patients.
Of interest is the fact that the mutations are unequally
distributed between the different exons (see fig. 1): six
mutations were found in exons 5 and 8, whereas no
mutation was found in exon 1. It is unlikely that the
first exon would accommodatemutations less easily than
would other exons, since its degree of conservation is
intermediate between those of exon 5 and exon 8
(Matthijs et al. 1997a). It is more probable that the
mutation-rate difference among exons is due to their
sequence context and position in the genome.
All mutations except one are missense mutations. It
is remarkable that, in this collection of mutations, only
a single frameshift mutation has been observed. The
G175R mutation might also affect splicing. Nineteen of
the mutations that were found affect residues that are
strictly conserved among PMMs (fig. 1 and table 3). This
supports the notion that mutations at these sites are
detrimental to the function of the protein. Also, the com-
parative data in figure 1 suggest that the list of mutations
presented here is not exhaustive. An alignment of PMM2
with PMM1, yeast SEC53, and Candida albicans PMM
has been published (Matthijs et al. 1997a). Enzymatic
studies of some of the mutant proteins are underway.
The R141Hmutation is by far themost frequent (Cau-
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Figure 2 Identification of a single-base-pair deletion in exon 2
of PMM2, by SSCP and sequencing in a patient with CDG1A.A, SSCP
analysis showing an aberrant pattern for patient RMan. B, Direct
sequencing using the fluorescent primer int4R, revealing a heterozy-
gous deletion of the G at position 324, which is the third base of codon
108. Downstream of the deletion site, the signal is a mixture of two
overlapping sequences. Note that the sequence of the antisense strand
is given. C, Effect of the deletion on the translational frame. The
frameshift results in a stop 19 codons downstream of the deletion site
(not shown).
Figure 3 Sequence analysis revealing the occurrence of the F119L mutation in the homozygous state. The results of the direct sequencing
are shown for (A) a normal control (homozygous for the normal sequence), (B) the father of patient SN (heterozygous), and (C) patient PG
(homozygous for the mutation). Codon 119 is boxed.
casian) one. The D188G mutation seems to be restricted
to Belgian (Flemish) and Dutch patients. The V44A mu-
tation is probably of Spanish origin, whereas the D65Y
mutation, homozygous in a Portuguese patient, is also
found in a French patient with Portuguese ancestors. The
V129M mutation might well be of Italian origin. We
have not tried to link the most frequently observed mu-
tations to a common haplotype of the flanking poly-
morphic markers, but it seems that some mutations are
old mutations that have been present in the different
populations for centuries. The R141H mutation is
caused by a CGCrCAC transition, but the equally likely
CGCrTGC transition (R141C, which is found in a proc-
essed pseudogene, derived from PMM2 and located on
chromosome 18p; see Schollen et al. 1998) has not been
observed in patients. Thus, the R141H mutation may
be an old mutation, like the frequent DF508 in cystic
fibrosis (Morral et al. 1993). On the other hand, some
mutations must have occurred independently on differ-
ent chromosomes in the different populations. For in-
stance, the R123G mutation, shared by two Spanish and
two Dutch patients, is syntenic with a polymorphism at
nucleotide 324 in the coding region and also has been
identified in a Japanese patient and in a French patient,
but without the polymorphism. The T237R and T237M
mutations are caused by CrT transitions on opposite
strands in the same CpG-dinucleotide. It is known that
CpG-dinucleotides are hot spots for mutations. An in-
teresting observation is that the corresponding CpGs
have also been mutated in the processed pseudogene
(Schollen et al. 1998).
A complex genotype has been observed in two fam-
ilies. DNA from the parents has been used to establish
the phase of these mutations. The A233T mutation is
syntenic with the T237R and T237M mutations in, re-
spectively, patient pair SN and SJ and patient LS,
whereas the T237R is present on the other allele in the
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family of the latter patient. Taken together, the alter-
native combinations of the T237R and T237M muta-
tions with the A233T mutation are remarkable, and the
occurrence of two different mutations in the same codon
on the two chromosomes in patient LS is intriguing.
Relationship between the Mutations and the
Phenotype
Very limited inferences can be made from the geno-
type-phenotype comparison. There is no clear correla-
tion between the PMM activities and the genotype in 6
and 14 patients with the R141H/P113L and R141H/
F119L combinations, respectively. It has previously been
remarked that a great variability exists in the clinical
expression among affected siblings (Jaeken et al. 1997b).
One significant observation is the high mortality in the
patients with the D188G/R141H genotype: four of five
patients died before the age of 2 years,whereas the fifth
patient, now age 10 years, is severely affected. On the
other hand, the twin patients, described originally by
Jaeken et al. (1980), are now age 21 years, are relatively
well, and have the R141H/P113L genotype. The R123G/
P113L genotype is observed in a Spanish patient with
pubertal development, which is not normally seen in
females with CDG1.
Even in the most severe cases, the bulk of N-linked
carbohydrate chains is present on serum glycoproteins.
This would mean that some residual activity is required.
The fact that mainly missense mutations are found sug-
gests that a total lack of PMM2 activity is incompatible
with life. The lack of homozygotes for R141H supports
this idea (see below). Thus far, alternative pathways to
bypass PMM activity and to generate mannose 1-phos-
phate have not been described.
Given the low frequency of CDG1, one would expect
this recessive disorder to be most frequently encountered
in consanguineous families. In our previous haplotype
analysis of 15 patients, we have not encountered ho-
mozygosity for a disease-associated haplotype of linked
markers (Matthijs et al. 1996). The molecular analysis
revealed the significant lack of homozygotes for R141H.
Thus, Hardy-Weinberg equilibrium is not reached, prob-
ably because of selection against this genotype. Probably,
R141H is a severe mutation that is deleterious in the
homozygous state, leading to fetal wastage, miscarriage,
or early death. It might also give rise to a different phe-
notype. In view of the fundamental role of PMM2 in
the normal functioning of the cell, we hypothesize that
it is lethal soon after conception. There are only two
ways to address this question. One is to try to find fam-
ilies in which both parents are carriers of R141H, to
prove that the R141H/R141H genotype is absent in their
children, and to look for an association with miscar-
riages. Given that the gene frequency is very low, this is
practically impossible. The other way is to await the
availability of a transgenic mouse model, to find out
whether the homozygous knockout is (embryonic) lethal
or results in a different phenotype.
Most other mutations must be relatively mild, because
they are found in association with R141H. In the recent
report on haplotype data from the Swedish group, Bjur-
sell et al. (1997) report at least two homozygous cases
in their population. On the basis of the complete lack
of R141H-homozygous patients in the present series, we
speculate that the underlying mutation will be a milder
mutation. In our series, patients were homozygous for
the D65Y and F119L mutations. The D65Y mutation
is rare, but the F119L mutation is frequent, and the
occurrence of one F119L/F119L patient in a series of
56 reflects Hardy-Weinberg equilibrium. This observa-
tion suggests that these are mild mutations. This might
be reflected by the relatively high value of the residual
PMM activity in fibroblasts of the D65Y/D65Y patient.
However, the sameD65Ymutation, in combinationwith
the R141H mutation, was found in a patient (patient 2)
with a severe phenotype, who died at a very young age.
The F119L/R141H genotype is especially frequent; thus,
the combination of the two most frequent disease mu-
tations is not lethal.
It remains to be investigated how these mutations af-
fect the function of the protein. Nothing is currently
known about the functional domains of PMMs. The
availability of a plethora of functional mutants will be
of great value in the interpretation of structural data.
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